China Medical System Holdings (HKEX: 00867), a Shenzhen-based specialty pharmaceutical company, registered a first-in-human clinical trial for CMS-D008, an siRNA therapeutic targeting the hepatokine INHBE (Inhibin Subunit Beta E) in adults with overweight or obesity. The trial, registered as NCT07518589, marks the company's most visible attempt to transition from a commercialisation-led business model toward internal drug discovery, and places it in a nascent but increasingly competitive class of RNA-based obesity therapies.
CMS-D008 appears to have been developed internally through Shenzhen Kangzhe Biotechnology Co., Ltd., the group's dedicated biotechnology subsidiary, which is listed as the clinical sponsor. China Medical System stated in March 2026 that it received an investigational new drug approval from China's National Medical Products Administration (NMPA) for the molecule, describing it as a self-developed asset.
The Phase I randomized, placebo-controlled study (n≈110) will assess single- and multiple-ascending doses, with endpoints focused on safety, pharmacokinetics, and immunogenicity. Primary completion is expected in Q4 2027. The eligibility criteria carry mechanistic significance. Participants must have HbA1c below 6.5% and fasting plasma glucose below 7 mmol/L at screening, excluding overt type 2 diabetes while permitting the metabolic phenotype most relevant to the INHBE pathway. Exclusion of participants with prior siRNA exposure reflects both immunogenicity considerations and the need for a clean pharmacological baseline.
The INHBE gene and obesity
The biological rationale for CMS-D008 draws on human genetic data linking loss-of-function variants in the INHBE gene to reduced fat mass and protection from metabolic disease. INHBE encodes Activin E, a TGF-β superfamily member secreted by the liver that signals through the ALK7 receptor (ACVR1C) on adipose tissue and skeletal muscle. Under normal physiology, Activin E suppresses lipolysis and promotes fat accumulation; its expression is elevated in obesity and insulin-resistant states. By silencing INHBE mRNA in hepatocytes via RNA interference, CMS-D008 aims to reduce circulating Activin E, thereby disinhibiting lipolytic enzyme activity and promoting selective fat loss.